JP5934805B2 - シュードモナスの生物学的防除方法 - Google Patents
シュードモナスの生物学的防除方法 Download PDFInfo
- Publication number
- JP5934805B2 JP5934805B2 JP2014548030A JP2014548030A JP5934805B2 JP 5934805 B2 JP5934805 B2 JP 5934805B2 JP 2014548030 A JP2014548030 A JP 2014548030A JP 2014548030 A JP2014548030 A JP 2014548030A JP 5934805 B2 JP5934805 B2 JP 5934805B2
- Authority
- JP
- Japan
- Prior art keywords
- pseudomonas
- amoeba
- magna
- deposit number
- atcc under
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000589516 Pseudomonas Species 0.000 title claims description 69
- 241000224489 Amoeba Species 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 21
- 230000012010 growth Effects 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000010865 sewage Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 241000500397 Willaertia magna Species 0.000 claims description 2
- 238000004378 air conditioning Methods 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims description 2
- 230000032770 biofilm formation Effects 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 239000008235 industrial water Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 22
- 238000003501 co-culture Methods 0.000 description 17
- 230000001580 bacterial effect Effects 0.000 description 13
- 241000224492 Hartmannella Species 0.000 description 11
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 239000006150 trypticase soy agar Substances 0.000 description 10
- 241000224423 Acanthamoeba castellanii Species 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 239000000645 desinfectant Substances 0.000 description 8
- 241000224422 Acanthamoeba Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000003211 trypan blue cell staining Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000009304 pastoral farming Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000589242 Legionella pneumophila Species 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 108010069584 Type III Secretion Systems Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940115932 legionella pneumophila Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000007260 scgyem-medium Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 241000224430 Acanthamoeba polyphaga Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 230000010699 Iron Chelating Activity Effects 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000320117 Pseudomonas putida KT2440 Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000224493 Vermamoeba vermiformis Species 0.000 description 1
- 241000500400 Willaertia Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000006477 glucose yeast extract medium Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000010842 industrial wastewater Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000018612 quorum sensing Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/10—Protozoa; Culture media therefor
- C12N1/105—Protozoal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/90—Protozoa ; Processes using protozoa
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
1.1.用いた株
シュードモナス(Pseudomonas):用いられた菌株は、CL5210菌株(Oxoid, France)である。
・ハルトマンネラベルミフォーミス(Hartomannellavermiformis)
・アカントアメーバカステラーニ(Acanthamoeba castellanii)(ATCCに30010番で寄託されている株)
・ウィラーティアマグナ(Willaeriamagna)(ATCCに寄託番号PTA 7824及びPTA 7825で寄託されている株)。
カゼイン(Merck 1.02244.010) 10g
Na2HPO4 1.325g
KH2PO4 0.8g
グルコース 2.5g
酵母エキス(Difco 0127-17-9) 5g
蒸留水 900ml
ウシ胎児血清 100ml。
1.2.1.接種菌の調製
無菌蒸留水とシュードモナスとの懸濁液は、550nmにおいて吸光度単位が1である、すなわち109CFU(colony-forming units)/mlとなるように、TSAで2日間培養されたものから調製される。
1.2.2.単一アメーバとの共培養の実施
共培養は、オートクレーブによる無菌水を3ml含む細胞培養チューブで行われる(Falcon3033)。予めMalassez血球計算盤でカウントされた無菌のアメーバ懸濁液から、1×105アメーバ/mlの割合でそのチューブへの播種が行われる。シュードモナスによるアメーバへの寄生は、シュードモナス/アメーバ比が10となる、すなわち培養培地において1×106細菌/mlとなるようにして行われる。寄生後すぐに、共培養チューブは、アメーバと細菌との接触を促進するために低速(760gで10分)で遠心機にかけられる。10分後、そのチューブは、手動で再懸濁され、30℃のインキュベータ内において傾けられた状態で培養される。
ウィラーティアは、TSA上に播種されたシュードモナスの層上に堆積された。その寒天培地は、寒天培地の表面に細菌の膜が生じるように、30℃で24時間置かれる。その後、1×105のアメーバ(アカントアメーバカステラーニ、ハルトマネラベルミフォーミス又はウィラーティアマグナ)は、寒天培地の中央に播かれ、30℃で24時間置かれる。その後、寒天培地は、そこで生じ得る細菌層溶解プラークの形成を検出するために光学顕微鏡(倍率×400)で観察される。
2.1.ウィラーティアマグナはシュードモナス抵抗性を示す
試験された種々のアメーバ種の生存におけるシュードモナスの影響は、トリパンブルー色素排除試験により測定された。アカントアメーバカステラーニを細菌と共培養した後、このアメーバ種において、共培養の3時間後の生存率が30%にまで低下するといった大きい細胞毒性効果が見られる(図1参照)。逆に、この現象は、ウィラーティアマグナをシュードモナスと共培養したときには見られず、9時間培養しても100%に近い生存率が維持されている(図1)。ウィラーティアマグナと同様に、自由生活ハルトマネラベルミフォーミスアメーバでは、トリパンブルー色素排除試験により測定された生存率に関して減少が見られない(図1)。これら全ての観察(シュードモナスにより誘導される被嚢形成及び細胞毒性が無い)は、ウィラーティアマグナ及びハルトマネラベルミフォーミスが、他のアメーバ種であるアカントアメーバカステラーニとは反対に、シュードモナスに抵抗する能力を示すことを証明する。
ハルトマンネラ及びアカントアメーバ属に属するアメーバの存在下で行われるシュードモナスの共培養の結果は、6時間後において細菌濃度の増加が見られるため(図2参照)、それら2つのアメーバ属の存在下における細菌のかなりの増殖を証明する。反対に(全く同一の条件で行われるにもかかわらず)、シュードモナスのみを含むコントロールと比較して、ウィラーティアマグナアメーバの存在下においては、検出可能なシュードモナスの約1logの減少が見られる(図2及び図3参照)。測定されるシュードモナスの濃度の減少は、シュードモナスに対するウィラーティアマグナの強力な捕食効果を証明する。
1. Abd H,Wretlind B, Saeed A, Idsund E, Hultenby K, and Sandstrom G. Pseudomonasaeruginosa utilises its type III secretion system to kill the free-livingamoeba Acanthamoeba castellanii. J Eukaryot Microbiol 55: -243.2008.
2. AshishA, Shaw M, Winstanley C, Ledson MJ, and Walshaw MJ. Increasing resistance ofthe Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) toantibiotics in cystic fibrosis (CF)-A cause for concern? J Cyst Fibros 2011.
3. BodennecJ, Dey R, and Pernin P. Novel method for biologically combating theproliferation of Legionella pneumophila, and novel disinfecting agentcontaining amoebic protozoa of the Willaertia genus. edited by University CBL.France: 2010.
4. BodeyGP, Bolivar R, Fainstein V, and Jadeja L. Infections caused by Pseudomonasaeruginosa. Rev Infect Dis 5: -313.1983.
5. BredenbruchF, Geffers R, Nimtz M, Buer J, and Haussler S. The Pseudomonas aeruginosaquinolone signal (PQS) has an iron-chelating activity. Environ Microbiol 8:-1329.2006.
6. DaviesB, Chattings LS, and Edwards SW. Superoxide generation during phagocytosis byAcanthamoeba castellanii: similarities to the respiratory burst of immune phagocytes.J Gen Microbiol 137: -710.1991.
7. FernandezM, Conde S, de la Torre J, Molina-Santiago C, Ramos JL, and Duque E. Mechanismsof resistance to chloramphenicol by Pseudomonas putida KT2440. AntimicrobAgents Chemother 2011.
8. Fones H,and Preston GM. Reactive oxygen and oxydative stress tolerance in plantpathogenic pseudomonas. FEMS Microbiol Lett doi:10.1111/j.1574-6968.2011.02449.x.[Epub ahead of print]: 2011.
9. Hahn MW,Moore ER, and Hofle MG. Role of Microcolony Formation in the ProtistanGrazing Defense of the Aquatic Bacterium Pseudomonas sp. MWH1. Microb Ecol 39:175-185, 2000.
10. IrazoquiJE, Troemel ER, Feinbaum RL, Luhachack LG, Cezairliyan BO, and Ausubel FM.Distinct pathogenesis and host responses during infection of C. elegans by P. aeruginosaand S. aureus. PloS Pathog 6: e1000982, 2010.
11. JuliaAG, and Morgan BM. The effects of selected strains of pigmented microorganismson small free-living amoeba. Can J Microbiol 10: -584.1964.
12. Matz C,Bergfeld T, Rice SA, and Kjelleberg S. Microcolonies, quorum sensing andcytotoxicity determine the survival of Pseudomonas aeruginosa biofilms exposedto protozoan grazing. Environ Microbiol 6: -226.2004.
13. Matz C,Moreno AM, Alhede M, Manefield M, Hauser AR, Givskov M, and Kjelleberg S. Pseudomonasaeruginosa uses type III secretion system to kill biofilm-associated amoebae.Isme J 2: 843-852.2008.
14. MichelR, Burghardt H, and Bergmann H. Acanthamoeba, naturally intracellularlyinfected with Pseudomonas aeruginosa, after their isolation from amicrobiologically contaminated drinking water system in a hospital. ZentralblHyg Umweltmed 196: -544.1995.
15. MolmeretM, Horn M, Wagner M, Santic M, and Abu Kwaik Y. Amoebae as training grounds forintracellular bacterial pathogens. Appl Environ Microbiol 71: 20-28, 2005.
16. QureshiMN, Perez AA, 2nd, Madayag RM, and Bottone EJ. Inhibition of Acanthamoebaspecies by Pseudomonas aeruginosa: rationale for their selective exclusion incorneal ulcers and contact lens care systems. J Clin Microbiol 31: -1910.1993.
17. Wang X,and Ahearn DG. Effect of bacteria on survival and growth of Acanthamoebacastellanii. Curr Microbiol 34: 212-215, 1997.
18. WeitereM, Bergfeld T, Rice SA, Matz C, and Kjelleberg S. Grazing resistance ofPseudomonas aeruginosa biofilms depends on type of protective mechanism,developmental stage and protozoan feeding mode. Environ Microbiol 7:-1601.2005.
19. Yang L,Jelsbak L, and Molin S. Microbial ecology and adaptation in cystic fibrosisairways. Environ Microbiol 13: 1682-1689.2011.
Claims (6)
- ATCCに寄託番号PTA 7824で寄託された株、又はATCCに寄託番号PTA7825で寄託された株に相当するウィラーティア(Willaertia)属のアメーバ性原生動物を対象に接触させることを特徴とし、ヒト又は動物の体に適用される治療方法を除く、シュードモナス(Pseudomonas)の増殖を抑制する方法。
- 気体若しくは液体の流れ、又は固体表面が、ウィラーティアマグナ(willaertia magna)種のアメーバ性原生動物を用いて処理されることを特徴とする請求項1に記載の方法。
- 下水若しくは工業用水の配水管網、工業プラントの冷却回路、空調ネットワーク又は工業製品の表面の消毒のために行われることを特徴とする請求項1に記載の方法。
- 水管内、又はヒト若しくは動物の食品に接触する可能性がある表面におけるバイオフィルムの形成を抑制するために行われることを特徴とする請求項1に記載の方法。
- 配管又はネットワーク内を循環する水又は液体中のシュードモナス(Pseudomonas)の殺菌のために、ATCCに寄託番号PTA7824で寄託された株、又はATCCに寄託番号PTA7825で寄託された株に相当する原生動物を前記水又は液体に加えることを含むシュードモナスの殺菌方法。
- 前記原生動物が水溶液又は懸濁液の形態で用いられることを特徴とする請求項5に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1162098A FR2984081A1 (fr) | 2011-12-20 | 2011-12-20 | Procede de lutte biologique contre les pseudomonas |
FR1162098 | 2011-12-20 | ||
PCT/EP2012/076451 WO2013092897A1 (fr) | 2011-12-20 | 2012-12-20 | Procede de lutte biologique contre les pseudomonas |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015508391A JP2015508391A (ja) | 2015-03-19 |
JP5934805B2 true JP5934805B2 (ja) | 2016-06-15 |
Family
ID=47435986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014548030A Active JP5934805B2 (ja) | 2011-12-20 | 2012-12-20 | シュードモナスの生物学的防除方法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US9288994B2 (ja) |
EP (1) | EP2809161B1 (ja) |
JP (1) | JP5934805B2 (ja) |
CN (1) | CN104302182B (ja) |
BR (1) | BR112014012966B1 (ja) |
CY (1) | CY1117588T1 (ja) |
DK (1) | DK2809161T3 (ja) |
ES (1) | ES2570386T3 (ja) |
FR (1) | FR2984081A1 (ja) |
HR (1) | HRP20160464T1 (ja) |
HU (1) | HUE027930T2 (ja) |
PL (1) | PL2809161T3 (ja) |
RS (1) | RS54777B1 (ja) |
RU (1) | RU2575999C2 (ja) |
SI (1) | SI2809161T1 (ja) |
WO (1) | WO2013092897A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3012014B1 (fr) * | 2013-10-23 | 2016-07-22 | Amoeba | Procede de lutte biologique contre naegleria fowleri, et agent desinfectant contenant des protozoaires de l'espece willaertia magna |
JP6404072B2 (ja) * | 2014-10-03 | 2018-10-10 | 株式会社シード | アカントアメーバの消毒評価方法 |
JP6506002B2 (ja) * | 2014-10-03 | 2019-04-24 | 株式会社シード | アカントアメーバ用培地 |
WO2018075626A1 (en) * | 2016-10-18 | 2018-04-26 | Viscus Biologics, Llc | Amoeba therapeutic dressings, biomaterials, and solutions |
FR3070004B1 (fr) | 2017-08-10 | 2020-12-25 | Amoeba | Utilisation therapeutique ou non-therapeutique de protozoaires du genre willaertia comme fongistatique et/ou fongicide |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61178907A (ja) * | 1985-01-18 | 1986-08-11 | Kao Corp | 殺生剤の生物効力を増強する殺生方法及び殺生剤用生物効力増強剤 |
CA2052343C (en) * | 1991-06-07 | 1997-11-04 | Fredric G. Bender | Process for treating animal carcasses to control bacterial growth |
WO2005070181A2 (en) * | 2004-01-13 | 2005-08-04 | Mastertaste | Low flavor anti-microbials drived from smoke flavors |
FR2906968B1 (fr) * | 2006-10-12 | 2010-09-17 | Univ Claude Bernard Lyon | Nouveau procede de lutte biologique contre la proliferation de legionella pneumophila, et nouvel agent desinfectant contenant des protozoaires amibiens du genre willaertia |
US8551471B2 (en) * | 2010-06-03 | 2013-10-08 | Amebagone, Llc | Therapeutic amoeba and uses thereof |
-
2011
- 2011-12-20 FR FR1162098A patent/FR2984081A1/fr not_active Withdrawn
-
2012
- 2012-12-20 US US14/365,237 patent/US9288994B2/en active Active
- 2012-12-20 CN CN201280062183.9A patent/CN104302182B/zh active Active
- 2012-12-20 BR BR112014012966-5A patent/BR112014012966B1/pt active IP Right Grant
- 2012-12-20 DK DK12806480.5T patent/DK2809161T3/en active
- 2012-12-20 JP JP2014548030A patent/JP5934805B2/ja active Active
- 2012-12-20 RU RU2014129836/10A patent/RU2575999C2/ru active
- 2012-12-20 PL PL12806480T patent/PL2809161T3/pl unknown
- 2012-12-20 ES ES12806480T patent/ES2570386T3/es active Active
- 2012-12-20 WO PCT/EP2012/076451 patent/WO2013092897A1/fr active Application Filing
- 2012-12-20 SI SI201230531A patent/SI2809161T1/sl unknown
- 2012-12-20 RS RS20160282A patent/RS54777B1/sr unknown
- 2012-12-20 HU HUE12806480A patent/HUE027930T2/en unknown
- 2012-12-20 EP EP12806480.5A patent/EP2809161B1/fr active Active
-
2016
- 2016-04-28 CY CY20161100364T patent/CY1117588T1/el unknown
- 2016-05-02 HR HRP20160464TT patent/HRP20160464T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2013092897A9 (fr) | 2013-09-19 |
RU2014129836A (ru) | 2016-02-10 |
CN104302182A (zh) | 2015-01-21 |
PL2809161T3 (pl) | 2016-08-31 |
RS54777B1 (sr) | 2016-10-31 |
SI2809161T1 (sl) | 2016-10-28 |
EP2809161A1 (fr) | 2014-12-10 |
ES2570386T3 (es) | 2016-05-18 |
HUE027930T2 (en) | 2016-11-28 |
BR112014012966B1 (pt) | 2019-07-02 |
FR2984081A1 (fr) | 2013-06-21 |
RU2575999C2 (ru) | 2016-02-27 |
DK2809161T3 (en) | 2016-05-09 |
JP2015508391A (ja) | 2015-03-19 |
EP2809161B1 (fr) | 2016-02-03 |
CY1117588T1 (el) | 2017-04-26 |
US20140322167A1 (en) | 2014-10-30 |
US9288994B2 (en) | 2016-03-22 |
BR112014012966A2 (pt) | 2017-06-13 |
HRP20160464T1 (hr) | 2016-08-12 |
WO2013092897A1 (fr) | 2013-06-27 |
CN104302182B (zh) | 2016-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5934805B2 (ja) | シュードモナスの生物学的防除方法 | |
Rukayadi et al. | In vitro antibacterial activity of panduratin A against enterococci clinical isolates | |
Pagedar et al. | Adaptation to benzalkonium chloride and ciprofloxacin affects biofilm formation potential, efflux pump and haemolysin activity of Escherichia coli of dairy origin | |
Khadke et al. | Inhibitory effects of honokiol and magnolol on biofilm formation by Acinetobacter baumannii | |
US8753691B2 (en) | Antiviral colloidal silver composition | |
JP5934804B2 (ja) | リステリアの生物的防除方法 | |
WO2019144830A1 (zh) | 一种宽裂解谱绿脓杆菌噬菌体及其消毒应用 | |
US8168167B2 (en) | Method for biologically combating the proliferation of Legionella pneumophila, and novel disinfecting agent containing amoebic protozoa of the Willaertia genus | |
Bokaeian et al. | The antibacterial activity of silver nanoparticles produced in the plant Sesamum indicum seed extract: a green method against multi-drug resistant Escherichia coli | |
Bonaterra et al. | Phenotypic comparison of clinical and plant-beneficial strains of Pantoea agglomerans | |
Milanov et al. | Examination of the capabilities of attachment and biofilm formation of different Listeria monocytogenes strains. | |
US9894903B2 (en) | Method for biologically combating Naegleria fowleri, and disinfecting agent containing protozoa of the species Willaertia magna | |
Lertcanawanichakul et al. | Bioactive Compound from Streptomyces sp. KB1 TISTR2504 as Effective Disinfectant against Microorganisms | |
Hammadi | Compression Effectiveness of Plant Extract by Using Magnetic Water and Ethanol on Some Pathogenic Bacteria | |
Caron | Characterization of Antibacterial Mechanisms of Zinc Oxide in Staphylococcus aureus | |
Amalia et al. | Antimicrobial activity of chitosan nanoparticles loaded with 0.7% tetracycline against porphyromonas gingivalis | |
Ali Al-Kaabi | THE USE OF BACTERIOPHAGES TO CONTROL LEGIONELLA SPP. IN ENVIRONMENTAL WATER SAMPLES | |
Grillo et al. | Evaluation of activity of dichloroxylenol (1.2% w/v) on Staphylococcus aureus Oxoid 701/1 Lot 610254 and clinical isolates of Escherichia coli and Salmonella typhi | |
Bonaterra i Carreras et al. | Phenotipic comparison of clinical and plant beneficial strains of Pantoea agglomerans | |
de Solis | Effect of plasmids that confer preservative-resistance on the performance of bacteria in preservative efficacy tests | |
US20120301529A1 (en) | Powder of vitreous composition having biocidal activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151119 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160419 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160509 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5934805 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |